TY - JOUR
T1 - Using interactive platforms to encode, manage and explore immune-related adverse outcome pathways
AU - Mazein, Alexander
AU - Shoaib, Muhammad
AU - Alb, Miriam
AU - Sakellariou, Christina
AU - Sommer, Charline
AU - Sewald, Katherina
AU - Reiche, Kristin
AU - Gogesch, Patricia
AU - Roser, Luise A.
AU - Ortega Iannazzo, Samira
AU - Sheth, Sapna
AU - Schiffmann, Susanne
AU - Waibler, Zoe
AU - Neuhaus, Vanessa
AU - Dehmel, Susann
AU - Satagopam, Venkata
AU - Schneider, Reinhard
AU - Ostaszewski, Marek
AU - Gu, Wei
N1 - Publisher Copyright:
© 2024 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
PY - 2024
Y1 - 2024
N2 - This work focuses on the need for modeling and predicting adverse outcomes in immunotoxicology to improve nonclinical assessments of the safety of immunomodulatory therapies. The integrated approach includes, first, the adverse outcome pathway concept established in the toxicology field, and, second, the systems medicine disease map approach for describing molecular mechanisms involved in a particular pathology. The proposed systems immunotoxicology workflow is illustrated with chimeric antigen receptor (CAR) T cell treatment as a use case. To this end, the linear adverse outcome pathway (AOP) is expanded into a molecular interaction model in standard systems biology formats. Then it is shown how knowledge related to immunotoxic events can be integrated, encoded, managed, and explored to benefit the research community. The map is accessible online at https://imsavar.elixir-luxembourg.orgvia the MINERVA Platform for browsing, commenting, and data visualization. Our work transforms a graphical illustration of an AOP into a digitally structured and standardized form, featuring precise and controlled vocabulary and supporting reproducible computational analyses. Because of annotations to source literature and databases, the map can be further expanded to match the evolving knowledge and research questions.
AB - This work focuses on the need for modeling and predicting adverse outcomes in immunotoxicology to improve nonclinical assessments of the safety of immunomodulatory therapies. The integrated approach includes, first, the adverse outcome pathway concept established in the toxicology field, and, second, the systems medicine disease map approach for describing molecular mechanisms involved in a particular pathology. The proposed systems immunotoxicology workflow is illustrated with chimeric antigen receptor (CAR) T cell treatment as a use case. To this end, the linear adverse outcome pathway (AOP) is expanded into a molecular interaction model in standard systems biology formats. Then it is shown how knowledge related to immunotoxic events can be integrated, encoded, managed, and explored to benefit the research community. The map is accessible online at https://imsavar.elixir-luxembourg.orgvia the MINERVA Platform for browsing, commenting, and data visualization. Our work transforms a graphical illustration of an AOP into a digitally structured and standardized form, featuring precise and controlled vocabulary and supporting reproducible computational analyses. Because of annotations to source literature and databases, the map can be further expanded to match the evolving knowledge and research questions.
KW - AOP
KW - CAR T cells
KW - CRS
KW - adverse outcome pathway
KW - chimeric antigen receptor
KW - cytokine release syndrome
KW - disease mechanisms
KW - immunomodulatory therapies
KW - systems biology
UR - http://www.scopus.com/inward/record.url?scp=85211774010&partnerID=8YFLogxK
U2 - 10.1080/1547691X.2024.2345154
DO - 10.1080/1547691X.2024.2345154
M3 - Article
C2 - 39655493
AN - SCOPUS:85211774010
SN - 1547-691X
VL - 21
SP - S5-S12
JO - Journal of Immunotoxicology
JF - Journal of Immunotoxicology
IS - sup1
ER -